Table 1 Summary of global multi-locus sequence typing studies*.

From: Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline

Study †

Origin ‡

Clinical origin §

Number of isolates

CC1 (ST1) ||

CC10

CC17

CC19 (ST19, 28) ||

CC23

CC26

Other

Jones5

World

Ca, Ninv, Ainv

152

16% (14%)

18%

30%

17% (13%–2%)

12%

2%

5%

Luan55

Sweden (1988–1997)

Ninv, Ainv

158

15% (9%)

13%

24%

29% (16%–1%)

14%

0

4%

Manning56

Canada Alberta (1993–2002)

Ca, Ninv

413

23% (19%)

14%

16%

20% (19%–NA)

22%

NA

5%

Bohnsack57

USA (1995–1999)

Ca, Ninv

899

16% (15%)

9%

13%

17% (12%–2%)

40%

0

5%

Sadowi58

Poland (1996–2005)

Ca, Ninv, Ainv

114

17% (13%)

18%

14%

12% (9–2%)

37%

1%

1%

Huber59

Kenya (2007–2010)

Ca, Ainv

169

12% (9%)

17%

21%

14% (5%–4%)

27%

2%

7%

Brochet7

Dakar Bangui (2006–2007)

Ca

163

20% (9%)

6%

12%

28% (4%–15%)

17%

15%

2%

  1. NA, Not available.
  2. *As percentage in each clonal complex.
  3. †First author of the publication and reference.
  4. ‡In parenthesis the years of isolation if known.
  5. §The epidemiological origin: Ca, carriage, Ninv, neonatal invasive disease, Ainv, adults invasive disease.
  6. ||In parenthesis, the percentage corresponding to the indicated sequence types (STs).
  7. Corresponds to strains from the closely related clonal complexes (CC) CC6, CC8 and CC10.
Back to article page